WebDisclosure WebDisclosure
Basculer en Français
11184 Companies
247341 Keywords
175191 Articles
133647 Press releases
Headlines Articles Press releases RedHill Biopharma Ltd. Remove
  1. Home
  2. Companies
  3. RedHill Biopharma Ltd.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 06/03/2026 at 18:15, 4 months 12 days ago

    RedHill Biopharma Explores Opaganib for Ebola Virus Amid Outbreak

    Clinical Trials Infectious Disease Ebola Virus Opaganib RedHill Biopharma
  • BRIEF

    published on 06/03/2026 at 18:15, 4 months 12 days ago

    RedHill Biopharma étudie l'opaganib pour le traitement du virus Ebola en pleine épidémie.

    Essais Cliniques Maladies Infectieuses Opaganib RedHill Biopharma Virus Ebola
  • PRESS RELEASE

    published on 06/03/2026 at 18:10, 4 months 12 days ago

    RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

    RedHill Biopharma is exploring collaboration opportunities to advance opaganib for Ebola virus disease outbreak, with potential host-directed therapeutic benefits and dual mechanism of action
    Collaboration Clinical Advancement Opaganib RedHill Biopharma Ebola Virus Disease
    Logo of RedHill Biopharma Ltd.
Accesswire
  • Published on 10/16/2026 at 05:55, 1 hour 32 minutes ago

    Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units

  • Published on 10/16/2026 at 02:10, 5 hours 17 minutes ago

    Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27

  • Published on 10/16/2026 at 01:45, 5 hours 42 minutes ago

    Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs

  • Published on 10/16/2026 at 01:30, 5 hours 57 minutes ago

    LNG Energy Group Announces Closing of Second Tranche of Private Placement

  • Published on 10/15/2026 at 23:08, 8 hours 19 minutes ago

    ACCESS Newswire to Present at the 20th Annual LD Micro Main Event XX - Tuesday October 20, 2026 - 11:00AM PT (2:00PM ET)

View all ACCESSWIRE
EQS Group
  • Published on 10/16/2026 at 07:00, 26 minutes ago

    PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.

  • Published on 10/15/2026 at 22:30, 8 hours 56 minutes ago

    Porsche Mission S: the essence of the sports car reinterpreted

  • Published on 10/15/2026 at 20:30, 10 hours 56 minutes ago

    Nordex Group reports strong preliminary Q3/2026 results and raises EBITDA margin guidance for full year 2026

  • Published on 10/15/2026 at 20:28, 10 hours 58 minutes ago

    EQS-Adhoc: Nordex SE: Nordex Group reports strong preliminary Q3/2026 results  and raises EBITDA margin guidance for full year 2026

  • Published on 10/15/2026 at 18:30, 12 hours 56 minutes ago

    Avolta's Q3 2026 trading update invitation

View all EQS
Les Echos
  • Published on 10/15/2026 at 18:50, 12 hours 37 minutes ago

    September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026

  • Published on 10/15/2026 at 18:50, 12 hours 37 minutes ago

    Trafic du mois de septembre et des 9 premiers mois de l'année 2026 - Révision des hypothèses de trafic pour l'année 2026

  • Published on 10/15/2026 at 18:16, 13 hours 10 minutes ago

    Déclaration des droits de vote au 30 septembre 2026

  • Published on 10/15/2026 at 18:14, 13 hours 12 minutes ago

    Déclaration des droits de vote au 31 août 2026

  • Published on 10/15/2026 at 18:00, 13 hours 27 minutes ago

    i2S : Chiffre d'Affaires T3 2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy